Latest Headlines
-
Ingersoll Rand to Acquire ILC Dover to Expand Presence in Life Sciences
3/25/2024
Ingersoll Rand Inc. (NYSE:IR), a global provider of mission-critical flow creation and industrial solutions, has entered into an agreement to acquire ILC Dover (“ILC”) from New Mountain Capital, LLC, a leading growth-oriented investment firm with approximately $50 billion in assets under management. The deal includes an upfront cash purchase price of approximately $2.325 billion and an earnout tied to the achievement of select operating efficiency metrics in 2024. At its maximum payout, the earnout
-
Honeywell Announces Upcoming Webinar and Conference Schedule
3/19/2024
Visit us at Booth 17 to learn more about our unified manufacturing operations platform and how it accelerates innovation and increases efficiency, quality, and compliance.
-
Pluri Selected As CDMO By Remedy Cell For Cell-Derived Cell-Free Drug Manufacturing
3/14/2024
Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today announced that its CDMO division (PluriCDMO™) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.
-
List Biotherapeutics And Sacco System Announce Lead Share Agreement
3/13/2024
List Biotherapeutics, Inc. (List Bio) and Sacco System Australia Pty Ltd (Sacco) today announced a lead share agreement to introduce and mutually recommend each other’s microbial development and manufacturing services to prospective customers if one party discovers a project that is better suited to the other party’s capability or capacity. No intellectual property will be exchanged between the companies.
-
FUJIFILM Diosynth Biotechnologies Announces Renewable Energy PPA With Better Energy For Denmark Manufacturing Site
2/29/2024
FUJIFILM Diosynth Biotechnologies, a world-leading CDMO for biologics, vaccines, advanced therapies and oncolytic viruses, has entered into a ten-year Power Purchase Agreement (PPA) to offtake 40 GWh of renewable energy annually with Better Energy, an integrated renewable energy company in Northern Europe.
-
CDMO Resilience Announces Modular Facility Design Investment At RTP Location
2/29/2024
National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, announced the expansion of the company’s clinical and commercial drug product manufacturing capabilities across its network, which includes a biomanufacturing plant in Durham the company acquired in 2021.
-
Simtra BioPharma Solutions Announces $250+M Investment To Expand Sterile Fill/Finish Manufacturing Site In Bloomington, Indiana
2/28/2024
Simtra BioPharma Solutions (Simtra), a premier injectable contract development and manufacturing organization (CDMO), today announced a $250+ million expansion of its sterile fill/finish manufacturing campus in Bloomington, Indiana.
-
5 Biologics Conferences You Won’t Want To Miss In 2024
2/23/2024
This list of recommended biologics conferences for 2024 can help guide professionals in the biologics industry to the most relevant and influential conferences for their professional goals.
-
AES Clean Technology Appoints New Vice President Of Engineering
2/22/2024
AES Clean Technology, a leading provider of high-performance modular cleanroom facilities, has appointed Chris Barbieri as Vice President of Engineering.
-
WuXi Advanced Therapies Receives FDA Approval To Manufacture Iovance’s AMTAGVI™ (lifileucel) For Advanced Melanoma
2/20/2024
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Drug Administration (FDA) has approved its Philadelphia site to begin the analytical testing and manufacturing of AMTAGVI for Iovance, which received FDA accelerated approval of its Biologics License Application (BLA) on February 16, 2024.